title: Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.
abstract: First-generation adenoviral (Ad) and high-capacity adenoviral (HC-Ad) vectors are efficient delivery vehicles for transferring therapeutic transgenes in vivo into tissues/organs. The initial successes reported with adenoviral vectors in preclinical trials have been limited by immune-related adverse side effects. This has been, in part, attributed to the use of poorly characterized preparations of adenoviral vectors and also to the untoward immune adverse side effects elicited when high doses of these vectors were used. HC-Ads have several advantages over Ads, including the lack of viral coding sequences, which after infection and uncoating, makes them invisible to the host's immune system. Another advantage is their large cloning capacity (up to approximately 35 kb). However, accurate characterization of HC-Ad vectors, and of contaminating replication-competent adenovirus (RCA) or helper virus, is necessary before these preparations can be used safely in clinical trials. Consequently, the development of accurate, simple, and reproducible methods to standardize and validate adenoviral preparations for the presence of contaminant genomes is required. By using a molecular method that allows accurate, reproducible, and simultaneous determination of HC-Ad, contaminating helper virus, and RCA genome copy numbers based on real-time quantitative PCR, we demonstrate accurate detection of these three genomic entities, within CsCl-purified vector stocks, total DNA isolated from cells transduced in vitro, and from brain tissue infected in vivo. This approach will allow accurate assessment of the levels and biodistribution of HC-Ad and improve the safety and efficacy of clinical trials.
authors.affiliation: Department of Medicine, Board of Governors' Gene Therapeutics Research Institute, Cedars-Sinai Medical Center, David Geffen School of Medicine, University of California Los Angeles, 90048, USA.
authors.forename: M
authors.initials: M
authors.lastname: Puntel
authors.forename: J F
authors.initials: JF
authors.lastname: Curtin
authors.forename: J M
authors.initials: JM
authors.lastname: Zirger
authors.forename: A K M
authors.initials: AK
authors.lastname: Muhammad
authors.forename: W
authors.initials: W
authors.lastname: Xiong
authors.forename: C
authors.initials: C
authors.lastname: Liu
authors.forename: J
authors.initials: J
authors.lastname: Hu
authors.forename: K M
authors.initials: KM
authors.lastname: Kroeger
authors.forename: P
authors.initials: P
authors.lastname: Czer
authors.forename: S
authors.initials: S
authors.lastname: Sciascia
authors.forename: S
authors.initials: S
authors.lastname: Mondkar
authors.forename: P R
authors.initials: PR
authors.lastname: Lowenstein
authors.forename: M G
authors.initials: MG
authors.lastname: Castro
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000302:isolation & purification; D000818:Animals; D001483:Base Sequence; D001681:Biological Assay; D001921:Brain / Q000821:virology; D002460:Cell Line; D004279:DNA, Viral / Q000378:metabolism; D005260:Female; D005822:Genetic Vectors / Q000009:adverse effects / Q000592:standards*; D016679:Genome, Viral; D006378:Helper Viruses / Q000235:genetics / Q000302:isolation & purification; D051379:Mice; D016133:Polymerase Chain Reaction / Q000379:methods* / Q000592:standards*
chemical_list: D004279:DNA, Viral